Table 3 Titers of antibody to hepatitis B surface antigen (anti-HBs) 2–4 weeks after the first vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive.

Slides:

Advertisements

Similar presentations

HEPATITIS A VIRUS Week Response Clinical illness ALT IgM IgG HAV in stool Infection Viremia EVENTS IN HEPATITIS A VIRUS INFECTION.

Advertisements

Figure 2 Power of likelihood ratio, log-rank, and Fisher’s exact tests as a function of the relative risk (RR) for different proportions of susceptible.

Table 4 Risk factors for acquisition of vancomycin-resistant enterococcal (VRE) colonization after transplantation for 120 liver transplant recipients.

In The Name of God.

Hepatitis B immune globulin

Table 5 Characteristics of 12 patients who had 1 test of stool samples that yielded positive results in the prospective clinical assessment for investigation.

Table 1. Baseline Characteristics of the 36,636 Study Subjects

Figure 1. Disposition of study participants, by group. Data are no

Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.

Evangelos Cholongitas, George V. Papatheodoridis, Andrew K. Burroughs

Table 4 Results of 3 pairwise comparisons of expanded virus groups, by use of least-squares means differences and the Tukey honestly significant difference.

Table 1. Prevalence of hepatitis B surface antigen (HBsAg) in west African cohorts from different countries. From: Low Genetic Diversity despite Hyperendemicity.

Table 1 Characteristics of patients at enrollment who received artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL) for treatment of malaria.

Table 3 Identification of Lactobacillus species isolated from blood cultures from Helsinki University Central Hospital, 1990–2000, and stored isolates.

L.S. Chathuranga, F. Noordeen, A.M.S.B. Abeykoon

Table 1 Demographic and clinical characteristics of 758 admitted patients for whom cultures of nares were performed to assess methicillin-resistant Staphylococcus.

Table 1 Characteristics of study patients in survey of HIV infection in India. From: Natural History of Human Immunodeficiency Virus Disease in Southern.

Table 3. Predictors of Nevirapine Reactions at Antiretroviral Therapy Initiation From: Strategies for Nevirapine Initiation in HIV-Infected Children Taking.

Table 4 Comparison of frequencies of Legionella pneumophila serogroup 1 urinary antigen results and antibody titer results among patients with Pontiac.

From: Rotarix: A Rotavirus Vaccine for the World

Volume 50, Issue 4, Pages (April 2009)

Figure 3. Estimated liver parasite load on day 6

Table 4. Effect of vaccination status on serogroup C serum bactericidal antibody (SBA) titers, IgG levels, and avidity indices (AIs) in acute and convalescent.

Figure 1. Prevalence of undocumented hepatitis C virus (HCV) infection, by age, race, and sex in 4713 emergency department patients, From: Evaluation.

Figure 4 Monthly all-cause (A-C) and pneumonia and influenza (P&I) mortality rates among Japanese children aged 5–9 years. Vertical dotted lines, January.

From: Postinfectious Irritable Bowel Syndrome

Figure 1 Adverse events after typhoid fever vaccination reported to the Vaccine Adverse Events Reporting System, by vaccination date and vaccine type,

Table 5 Sample format for results of Streptococcus pneumoniae isolate testing in a laboratory that routinely performs only oxacillin disk tests for penicillin.

Table 1 Baseline (before receipt of antiretroviral prophylaxis) characteristics of the pregnant women (transmitting or nontransmitting mothers included.

Figure 1 Annual per-capita consumption of all fermented milks and yogurt only in selected countries in Europe and North America [3, 4]. From: Probiotic.

Figure 1 Flow chart distinguishing groups according to receipt of azithromycin treatment and method of data collection. Circles containing the abbreviation.

Table 2. Mean intrasubject diversity for the 11 study participants, by genomic region. From: Hepatitis C Virus (HCV) Diversity in HIV-HCV-Coinfected Subjects.

Figure 3. Changes from baseline in activated CD4+ T cells (% CD4+CD25+) during the 52-week intervention period in the.

R. Cavallo Clinical Microbiology and Infection

Risk of Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy’s Law and a New Prognostic Model Vincent Lo Re, Kevin Haynes,

Effect of highly active anti-retroviral therapy and hepatitis C virus co-infection on serum levels of pro-inflammatory and immunoregulatory cytokines.

Volume 148, Issue 7, Pages e3 (June 2015)

Viral Hepatitis Among Somali Immigrants in Minnesota: Association of Hepatitis C With Hepatocellular Carcinoma Abdirashid M. Shire, PhD, Dalbir S. Sandhu,

Core I97L mutation in conjunction with P79Q is associated with persistent low HBV DNA and HBs antigen clearance in patients with chronic hepatitis B

Prevalence of human herpesvirus 8 and hepatitis C virus in a rural community with a high risk for blood-borne infections in central China T. Zhang, N.

Influence of hepatitis C and hepatitis G virus co-infection on viral and cellular dynamics in patients infected with human immunodeficiency virus following.

Hepatitis Primary Care: Clinics in Office Practice

Combining rapid diagnostic tests and dried blood spot assays for point-of-care testing of human immunodeficiency virus, hepatitis B and hepatitis C infections.

Hepatitis B and C virus-related carcinogenesis

Virological tools to diagnose and monitor hepatitis C virus infection

Introduction The American Journal of Medicine

Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B W.-K. Seto, D. K.-H. Wong,

Evangelos Cholongitas, George V. Papatheodoridis, Andrew K. Burroughs

Important Elements for the Diagnosis of Drug-Induced Liver Injury

Efficacy of Serologic Marker Screening in Identifying Hepatitis B Virus Infection in Organ, Tissue, and Cell Donors Dominique Challine, Stéphane Chevaliez,

A. Zeytinoğlu, S. Erensoy, H. Abacioğlu, A. A. Sayiner, T. Özacar, A

L. -W. Song, P. -G. Liu, C. -J. Liu, T. -Y. Zhang, X. -D. Cheng, H. -L

CHAPTER 10 Hepatitis on Dialysis

Estimation of delay in detecting hepatitis C virus antibodies in pools compared to individual testing on seroconversion panels B. Sarov, L. Novack, N.

Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice J.E. Arends, P.A.M. Kracht, A.I.M. Hoepelman Clinical.

Figure 1. Overview of protein microarray titers for all hemagglutinin (HA) part antigens, by diet and species. Antigens ... Figure 1. Overview of protein.

Evolution of the prevalence of hepatitis C virus infection and hepatitis C virus genotype distribution in human immunodeficiency virus-infected patients.

Serum hepatitis B core-related antigen is more accurate than hepatitis B surface antigen to identify inactive carriers, regardless of hepatitis B virus.

Hepatitis B and C virus-related carcinogenesis

S8 – S47 and O50 – O440 Clinical Microbiology and Infection

Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected.

Volume 50, Issue 4, Pages (April 2009)

Factors related to the chronicity and evolution of hepatitis C infection in patients coinfected by the human immunodeficiency virus R. Pérez-Cano, C.

Facilitating learning and change in physicians: Implications for a system of continuing medical education in Europe Robert D. Fox Clinical Microbiology.

Katherine A. Barraclough, E. Geoffrey Playford Kidney International

Volume 67, Issue 3, Pages (March 2005)

High prevalence of GB virus C/hepatitis G virus infection in different risk groups of HIV- infected patients P. Clevenbergh, J. Durant, P. Halfon, A.

S.-H. Kung, S.-F. Wang, C.-W. Huang, C.-C. Hsu, H.-F. Liu, J.-Y. Yang

Share your thoughts on this presentation with #IAS2019

Share your thoughts on this presentation with #IAS2019

Presentation transcript:

Table 3 Titers of antibody to hepatitis B surface antigen (anti-HBs) 2–4 weeks after the first vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive Subjects Who Test Positive for Isolated Antibody to Hepatitis B Core Antigen: Implications for Hepatitis B Vaccine Strategies J Infect Dis. 2005;191(9):1435-1441. doi:10.1086/429302 J Infect Dis | © 2005 by the Infectious Diseases Society of America

Table 2 Baseline characteristics of HIV-1–positive subjects who received hepatitis B vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive Subjects Who Test Positive for Isolated Antibody to Hepatitis B Core Antigen: Implications for Hepatitis B Vaccine Strategies J Infect Dis. 2005;191(9):1435-1441. doi:10.1086/429302 J Infect Dis | © 2005 by the Infectious Diseases Society of America

Table 1 Univariable analysis of risk variables for antibody to hepatitis B core antigen (anti-HBc) in HIV-1–positive subjects who tested negative for hepatitis B surface antigen (HBsAg) and antibody to HBsAg From: Response to Hepatitis B Vaccine in HIV-1–Positive Subjects Who Test Positive for Isolated Antibody to Hepatitis B Core Antigen: Implications for Hepatitis B Vaccine Strategies J Infect Dis. 2005;191(9):1435-1441. doi:10.1086/429302 J Infect Dis | © 2005 by the Infectious Diseases Society of America

Figure 1 Lower proportion of hepatitis C virus (HCV)–positive subjects with high titers of antibody to hepatitis B surface antigen (anti-HBs) after 3 vaccinations with hepatitis B vaccine, compared with HCV-negative subjects. The anti-HBs titer was measured 4 weeks after the third hepatitis B vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive Subjects Who Test Positive for Isolated Antibody to Hepatitis B Core Antigen: Implications for Hepatitis B Vaccine Strategies J Infect Dis. 2005;191(9):1435-1441. doi:10.1086/429302 J Infect Dis | © 2005 by the Infectious Diseases Society of America